Alethea Capital Management’s Immuneering IMRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.94M Hold
472,935
– – 0.99% 5
2026
Q2
$2.36M Buy
472,935
+450,000
+1,962% +$2.28M 0.98% 4
2026
Q1
$121K Hold
22,935
– – 0.06% 12
2025
Q4
$151K Hold
22,935
– – 0.07% 11
2025
Q3
$161K Hold
22,935
– – 0.1% 31
2025
Q2
$77.3K Buy
+22,935
New +$39.3K 0.06% 29

Other funds holding IMRX

Alethea Capital Management's IMRX Position: Q3 2026 in Review

Alethea Capital Management held its Immuneering (IMRX) position steady in Q3 2026 at 472,935 shares worth $1.94M. The position accounts for 0.99% of the portfolio, ranked #5.

Alethea Capital Management first reported a position in IMRX in Q2 2025 and has held it in 6 quarters since. The position peaked at $2.36M in Q2 2026. 131 funds tracked by Wall St. Rank hold IMRX as of Q3 2026.

  • Alethea Capital Management held 472,935 shares of Immuneering worth $1.94M as of Q3 2026.
  • Alethea Capital Management left its Immuneering share count unchanged in Q3 2026.
  • Immuneering made up 0.99% of Alethea Capital Management's portfolio in Q3 2026, its #5 holding.
  • Alethea Capital Management first reported a position in Immuneering in Q2 2025 and has held it in 6 quarters since.
  • Alethea Capital Management's Immuneering position peaked at $2.36M in Q2 2026.
  • 131 funds tracked by Wall St. Rank held Immuneering as of Q3 2026.

Based on Alethea Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.